Skip to main content
S&P 5007,610.34+0.32%DOW52,028.07-0.12%NASDAQ26,153.23+0.66%BTC$75,823.00-0.63%ETH$2,399.06-1.94%GOLD$4,386.20+1.23%OIL$103.57-2.14%
Smart Investors Daily
AR

AMEX · ARMP

Armata Pharmaceuticals, Inc.

Healthcare · Biotechnology

$4.40

Down-$0.06 (-1.25%)

Updated Sep 16, 2026, 1:50 PM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
391.74M
P/E ratio
-8.31
Dividend yield
0.00%
52-week range
$3.40 – $16.34
Volume
650.23K
Avg. volume
51.66K

Price performance

ARMP price history

1M range · 20 trading sessions · Daily adjusted prices

ARMP closed at $4.40 after 20 trading sessions, down 3.51% for the selected period.

Last close
$4.40
Period change
-3.51%
Period low
$4.40
Period high
$5.84
Daily close
View OHLC price history
ARMP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$5.24$5.35$4.23$4.40650.23K
Sep 14, 2026$6.17$6.6397$4.73$5.554.74M
Sep 11, 2026$5.30$5.5499$5.26$5.3843.63K
Sep 10, 2026$5.39$5.74$5.12$5.23115.38K
Sep 9, 2026$5.76$5.79$5.40$5.4117.89K
Sep 8, 2026$5.76$5.88$5.59$5.8247.38K
Sep 4, 2026$5.49$5.865$5.48$5.8448.03K
Sep 3, 2026$5.53$5.615$5.20$5.5249.5K
Sep 2, 2026$5.36$5.62$5.2708$5.5370.07K
Sep 1, 2026$5.51$5.68$5.19$5.2846.46K
Aug 31, 2026$5.35$5.52$5.18$5.5151.49K
Aug 28, 2026$5.37$5.445$4.985$5.3749.71K
Aug 27, 2026$5.42$5.47$4.73$5.43270.46K
Aug 26, 2026$5.59$5.59$5.30$5.4562.21K
Aug 25, 2026$5.23$5.70$5.23$5.5694.29K
Aug 24, 2026$5.10$5.26$4.862$5.1767.74K
Aug 21, 2026$4.42$5.10$4.42$5.10111.49K
Aug 20, 2026$4.98$5.17$4.12$4.42222.16K
Aug 19, 2026$4.61$5.10$4.61$5.07104.72K
Aug 18, 2026$4.44$4.665$4.44$4.5635.95K

Latest ARMP news

The latest Smart Investors Daily articles mentioning ARMP.

Stock researchCompany · Overview

ARMP research

Overview

Company profile and research snapshot.

Company profile

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$9.00
Implied upside
—
Analysts
—
ARMP recent ratings
DateFirmRatingTarget
Feb 23, 2026HC Wainwright & Co.Buy—
Jan 5, 2026Jones TradingBuy—
May 19, 2025HC Wainwright & Co.Buy—
Dec 19, 2024HC Wainwright & Co.Buy—
Nov 14, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced a paper in the Journal of Molecular Biology, a peer-reviewed journal.

Yahoo · Aug 13, 2026

Bronchiectasis Market is Expected to Surge at a CAGR of 15% by 2036, Owing to the Launch of DPP1/CatC Inhibitors, Therapeutic Phage Cocktails, Nebulized Mucoactive Agents, and Other Novel Mechanisms | DelveInsight

Recently published Bronchiectasis Market Insights report includes a comprehensive understanding of current treatment practices, bronchiectasis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Yahoo · Aug 12, 2026

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2026, and provided a corporate update.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By